Ayala Pharmaceuticals Inc (ADXS)

[ubmmg]

The huge run in 2015 was launched on nothing.

Disagree.
1) It was a biotech hysteria, immuno-oncology was hot area, and CAR-Ts showing great data for hematology. Our tech was relatively new. But we lacked the data, at least, great data.
2) We run in tandem with ADRO when they IPO'd. Adage's and Broadfin's participation drove us to $30.
3) j&e effect. Now his clones are now mostly single-celled.

Time waits for no one. We are late to the party...